Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis

Documenti analoghi

• Editorial comment on “Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis”
  di: Umit Murat Sahiner, et al.
  Pubblicazione: (2024)
• Long‐term comparison of high‐ and low‐dose oral immunotherapy in children with anaphylactic cow's milk allergy
  di: Yu Ito, et al.
  Pubblicazione: (2025)
• Reply to Gonzalez‐Labrador et al.
  di: Yuki Sakaguchi, et al.
  Pubblicazione: (2025)
• Low‐dose oral immunotherapy with Lacticaseibacillus rhamnosus GG for severe peanut allergy
  di: Noriyuki Yanagida, et al.
  Pubblicazione: (2025)
• Timing of initial symptom onset during milk and wheat challenges: A retrospective study
  di: Noriyuki Yanagida, et al.
  Pubblicazione: (2024)